Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
176 hedge funds and large institutions have $304M invested in Esperion Therapeutics in 2024 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 50 increasing their positions, 26 reducing their positions, and 30 closing their positions.
102% more call options, than puts
Call options by funds: $7.09M | Put options by funds: $3.5M
92% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 26
87% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 30
15% more funds holding
Funds holding: 153 → 176 (+23)
4.52% more ownership
Funds ownership: 67.81% → 72.33% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
10% less capital invested
Capital invested by funds: $336M → $304M (-$32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.2M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$18.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.54M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$5.66M |
| 5 |
WCM
Whitefort Capital Management
New York
|
+$5.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$36.7M |
| 2 |
D.E. Shaw & Co
New York
|
-$11.2M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$7.96M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$6.76M |
| 5 |
Goldman Sachs
New York
|
-$5.76M |
ESPR Hedge Fund Activity: Q2 2024 in Review
176 of the 6,935 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q2 2024, worth a combined $304M — down 9.5% from $336M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new ESPR positions and 30 closed out — a net gain of 26 holders — while 50 added to existing stakes and 26 trimmed.
The largest buyer was BlackRock, adding an estimated $26.2M. The largest seller was OrbiMed, exiting entirely with an estimated $36.7M sold.
- 176 institutional investors held Esperion Therapeutics (ESPR) as of Q2 2024, up from 153 in Q1 2024.
- Funds reported $304M of Esperion Therapeutics stock for Q2 2024, down 9.5% quarter-over-quarter.
- 56 funds opened new Esperion Therapeutics positions in Q2 2024 and 30 closed out, a net change of +26 holders.
- The largest Esperion Therapeutics buyer in Q2 2024 was BlackRock, an estimated $26.2M added.
- The largest Esperion Therapeutics seller in Q2 2024 was OrbiMed, an estimated $36.7M sold.
Based on aggregated 13F filings for Q2 2024.